DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 2, Issue 6, 2010, Pages 654-669

  Sharma, Amy ^a   Heuck, Christoph J ^a   Fazzari, Melissa J ^a   Mehta, Jayesh ^b   Singhal, Seema ^b   Greally, John M ^a   Verma, Amit ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; MICRORNA; TUMOR SUPPRESSOR PROTEIN; UNTRANSLATED RNA;

BIOLOGICAL MODEL; CHROMATIN; CYTOLOGY; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MULTIPLE MYELOMA; NEOPLASM; REVIEW; STEM CELL;

CHROMATIN; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; MICRORNAS; MODELS, GENETIC; MULTIPLE MYELOMA; NEOPLASMS; RNA, UNTRANSLATED; STEM CELLS; TUMOR SUPPRESSOR PROTEINS;

EID: 79952201738     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.89     Document Type: Review

References (99)

1. Singal R, Ginder GD. DNA methylation. Blood 1999, 93:4059-4070.
2. Duncan BK,Miller JH.Mutagenic deamination of cytosine residues in DNA. Nature 1980, 287:560-561.
3. Fazzari MJ, Greally JM. Epigenomics: beyond CpG islands. Nat Rev Genet 2004, 5:446-455.
4. Cross SH, Bird AP. CpG islands and genes. Curr Opin Genet Dev 1995, 5:309-314.
5. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992, 69:915-926.
6. Shukla V, Vaissiere T, Herceg Z. Histone acetylation and chromatin signature in stem cell identity and cancer. Mutat Res 2008, 637:1-15.
7. van Holde K. Chromatin. New York: Springer-Verlag; 1989.
8. Malik HS, Henikoff S. Phylogenomics of the nucleosome. Nat Struct Biol 2003, 10:882-891.
9. Jenuwein T, Allis CD. Translating the histone code. Science 2001, 293:1074-1080.
10. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000, 403:41-45.
11. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002, 12:198-209.
12. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001, 15:2343-2360.
13. Fischle W, Wang Y, Allis CD. Histone and chromatin cross-talk. Curr Opin Cell Biol 2003, 15:172-183.
14. Shukla A, Chaurasia P, Bhaumik SR. Histone methylation and ubiquitination with their cross-talk and roles in gene expression and stability. Cell Mol Life Sci 2008, 66:1419-1433.
15. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007, 130:77-88.
16. Ooi SK, Qiu C, Bernstein E, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007, 448:714-717.
17. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009, 10:295-304.
18. Eden S, Hashimshony T, Keshet I, Cedar H, Thorne AW. DNA methylation models histone acetylation. Nature 1998, 394:842.
19. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997, 88:471-481.
20. Ballestar E, PazMF, Valle L, et al.Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 2003, 22:6335-6345.
21. Schlesinger Y, Straussman R, Keshet I, et al. Polycombmediated methylation on Lys27 of histone H3 premarks genes for de novo methylation in cancer. Nat Genet 2007, 39:232-236.
22. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 128:683-692.
23. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5:522-531.
24. Rouhi A, Mager DL, Humphries RK, Kuchenbauer F. MiRNAs, epigenetics, and cancer. Mamm Genome 2008, 19:517-525.
25. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006, 94:776-780.
26. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
27. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524-15529.
28. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101:2999-3004.
29. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005, 122:6-7.
30. Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007, 67:1424-1429.
31. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
32. Katayama S, Tomaru Y, Kasukawa T, et al. Antisense transcription in the mammalian transcriptome. Science 2005, 309:1564-1566.
33. Yu W, Gius D, Onyango P, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008, 451:202-206.
34. Tufarelli C, Stanley JA, Garrick D, et al. Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat Genet 2003, 34:157-165.
35. Espada J, Ballestar E, Fraga MF, et al. Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern. J Biol Chem 2004, 279:37175-37184.
36. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
37. Warnecke PM, Bestor TH. Cytosine methylation and human cancer. Curr Opin Oncol 2000, 12:68-73.
38. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4:143-153.
39. Ng MH, Wong IH, Lo KW. DNA methylation changes andmultiplemyeloma. Leuk Lymphoma 1999, 34:463-472.
40. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455.
41. Bestor TH. Transposons reanimated in mice. Cell 2005, 122:322-325.
42. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159.
43. Lohrum M, Stunnenberg HG, Logie C. The new frontier in cancer research: deciphering cancer epigenetics. Int J Biochem Cell Biol 2007, 39:1450-1461.
44. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 1989, 83:155-158.
45. Kastrinakis NG, Gorgoulis VG, Foukas PG, Dimopoulos MA, Kittas C. Molecular aspects of multiple myeloma. Ann Oncol 2000, 11:1217-1228.
46. Alexander DD, Mink PJ, Adami HO, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007, 120(Suppl. 12):40-61.
47. Seidl S, Ackermann J, Kaufmann H, et al. DNAmethylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 2004, 100:2598-2606.
48. Chim CS, Fung TK, Liang R. Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia 2003, 17:2533-2535.
49. Chim CS, Kwong YL, Fung TK, Liang R. Methylation profiling in multiple myeloma. Leuk Res 2004, 28:379-385.
50. Uchida T, Kinoshita T, Ohno T, Ohashi H, Nagai H, et al. Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia. Leukemia 2001, 15:157-165.
51. Guillerm G, Depil S, Wolowiec D, Quesnel B. Different prognostic values of p15(INK4b) and p16(INK4a) genemethylations inmultiplemyeloma. Haematologica 2003, 88:476-478.
52. Guillerm G, Gyan E, Wolowiec D, et al. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 2001, 98:244-246.
53. Galm O, Wilop S, Reichelt J, et al. DNA methylation changes in multiple myeloma. Leukemia 2004, 18:1687-1692.
54. Chiusolo P, Farina G, Putzulu R, et al. Analysis of MTHFRpolymorphisms and P16 methylation and their correlation with clinical-biological features of multiple myeloma. Ann Hematol 2006, 85:474-477.
55. Gonzalez-Paz N, Chng WJ, McClure RF, et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007, 109:1228-1232.
56. Ribas C, Colleoni GW, Felix RS, et al. p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma. Cancer Lett 2005, 222:247-254.
57. Mateos MV, Garcia-Sanz R, Lopez-Perez R, et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002, 118:1034-1040.
58. Dib A, Barlogie B, Shaughnessy JD, Kuehl WM, Jr. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 2007, 109:1337-1338.
59. Chim CS, Liang R, Leung MH, Kwong YL. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J Clin Pathol 2007, 60:104-106.
60. Deligezer U, Erten N, Akisik EE, Dalay N.Methylation of the INK4A/ARF locus in blood mononuclear cells. Ann Hematol 2006, 85:102-107.
61. Lavelle D, DeSimone J, Hankewych M, Kousnetzova T, Chen YH. Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leuk Res 2003, 27:999-1007.
62. Ng MH, To KW, Lo KW, et al. Frequent deathassociated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res 2001, 7:1724-1729.
63. Chim CS, Liang R, Fung TK, Choi CL, Kwong YL. Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol 2007, 60:664-669.
64. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 2004, 103:4630-4635.
65. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003, 101:2784-2788.
66. Depil S, Saudemont A, Quesnel B. SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. Leukemia 2003, 17:1678-1679.
67. Reddy J, ShivapurkarN, Takahashi T, et al.Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 2005, 24:732-736.
68. Chim CS, Liang R, Fung TK, Kwong YL. Infrequent epigenetic dysregulation of CIP/KIP family of cyclindependent kinase inhibitors in multiple myeloma. Leukemia 2005, 19:2352-2355.
69. Song YF, Xu R, Zhang XH, et al. High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma. J Clin Pathol 2006, 59:947-951.
70. Hurt EM, Thomas SB, Peng B, Farrar WL. Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator. Cancer Biol Ther 2006, 5:1154-1160.
71. Takada S, Morita K, Hayashi K, et al.Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. Eur J Haematol 2005, 75:505-510.
72. Tatetsu H, Ueno S, Hata H, et al. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res 2007, 67:5328-5336.
73. Turner JG, Gump JL, Zhang C, et al. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 2006, 108:3881-3889.
74. Murai M, Toyota M, Satoh A. et al. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br J Cancer 2005, 92:1165-1172.
75. Wang Z, Zhang Y, Ramsahoye B, Bowen D, Lim SH. Sp17 gene expression in myeloma cells is regulated by promoter methylation. Br J Cancer 2004, 91:1597-1603.
76. Wang Z, Zhang J, Zhang Y, Lim SH. SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically. Int J Cancer 2006, 118:1436-1444.
77. Peng B, Hodge DR, Thomas SB, et al. Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsivemultiplemyeloma KAS-6/1 cells. J Biol Chem 2005, 280:4182-4187.
78. Peng B, Hurt EM, Hodge DR, Thomas SB, Farrar WL. DNA hypermethylation and partial gene silencing of human thymine-DNA glycosylase in multiple myeloma cell lines. Epigenetics 2006, 1:138-145.
79. Martin P, Santon A, Garcia-CosioM, Bellas C. hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies. Mod Pathol 2006, 19:914-921.
80. Chim CS, Pang R, Fung TK, Choi CL, Liang R. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 2007, 21:2527-2536.
81. Hodge DR, Peng B, Pompeia C, et al. Epigenetic silencing of manganese superoxide dismutase (SOD-2) in KAS 6/1 human multiple myeloma cells increases cell proliferation. Cancer Biol Ther 2005, 4:585-592.
82. Drucker L, Tohami T, Tartakover-Matalon S, et al. Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines. Carcinogenesis 2006, 27:197-204.
83. Houde C, Li Y, Song L, et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004, 104:3697-3704.
84. Bacolla A, Pradhan S, Larson JE, Roberts RJ, Wells RD. Recombinant human DNA (cytosine-5) methyltransferase. III. Allosteric control, reaction order, and influence of plasmid topology and triplet repeat length on methylation of the fragile X CGG.CCG sequence. J Biol Chem 2001, 276:18605-18613.
85. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
86. Hodge DR, Peng B, Cherry JC, et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 2005, 65:4673-4682.
87. Kiziltepe T,Hideshima T, Catley L, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATRmediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib againstmultiplemyeloma cells. Mol Cancer Ther 2007, 6:1718-1727.
88. Heller G, Schmidt WM, Ziegler B, et al. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res 2008, 68:44-54.
89. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640.
90. Figueroa ME, Reimers M, Thompson RF, et al. An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One 2008, 3:e1882.
91. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114:3448-3458.
92. Pompeia C, Hodge DR, Plass C, et al. Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line. Cancer Res 2004, 64:3465-3473.
93. Hodges E, Smith AD, Kendall J, et al. High definition profiling ofmammalianDNAmethylation by array capture and single molecule bisulfite sequencing. Genome Res 2009, 19:1593-1605.
94. Weber M, Davies JJ, Wittig D et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005, 37:853-862.
95. Irizarry RA, Ladd-Acosta C, Carvalho B, et al. Comprehensive high-throughput arrays for relativemethylation (CHARM). Genome Res 2008, 18:780-790.
96. Khulan B, Thompson RF, Ye K, et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res 2006, 16:1046-1055.
97. Figueroa ME,Wouters BJ, Skrabanek L, et al. Genomewide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/Tlymphoid features. Blood 2009, 113:2795-2804.
98. Ball MP, Li JB, Gao Y, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009, 27:361-368.
99. Sohal D, Yeatts A, Ye K, et al. Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration. PLoS One 2008, 3:e2965.